Mirum reports Q2 revenue $37.5M, LIVMARLI sales $32.5M; acquires CHENODAL/CHOLBAM for $210M

Mirum Pharmaceuticals, Inc.

Q2 total revenue $37.5M (incl $5M license); LIVMARLI net sales $32.5M, up 86% YoY.
Acquiring CHENODAL and CHOLBAM from Travere for $210M upfront + up to $235M milestones.
Entered $210M private placement to fund acquisition; closed $316.3M convertible notes at 4% due 2029.
Pipeline readouts H2 2023: EMBARK (biliary atresia), volixibat PSC/PBC, CHENODAL RESTORE.
Cash $330M as of June 30; repurchased 9.75% royalty obligation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Mirum Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: revenue $37.5 million.

Period: the quarter ended June 30, 2023
Revenue: $37.5 million
Result: reported results

Exact text from the filing

Total revenue for the quarter ended June 30, 2023 was $37.5 million, including $5.0 million of license revenue, compared to $17.5 million in total revenue for the quarter ended June 30, 2022.

View on SEC.gov

Browse all earnings releases →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001157523-23-001254

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.